1. HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy.
- Author
-
Lisker-Melman, Mauricio, Wahed, Abdus, Ghany, Marc, Chung, Raymond, King, Wendy, Kleiner, David, Bhan, Atul, Jain, Mamta, Sulkowski, Mark, Wong, David, Cloherty, Gavin, Sterling, Richard, and Khalili, Mandana
- Subjects
Adult ,Humans ,Male ,Middle Aged ,Biomarkers ,Coinfection ,Cross-Sectional Studies ,DNA ,Viral ,Hepatitis B Core Antigens ,Hepatitis B e Antigens ,Hepatitis B Surface Antigens ,Hepatitis B virus ,Hepatitis B ,Chronic ,HIV Infections ,RNA ,Viral Transcription ,Anti-Retroviral Agents ,Protein Biosynthesis - Abstract
BACKGROUND AND AIMS: Liver injury may persist in patients with HBV receiving antiviral therapy who have ongoing transcription and translation. We sought to assess ongoing HBV transcription by serum HBV RNA, translation by serum hepatitis B core related antigen (HBcrAg), and their associations with hepatic HBsAg and HBcAg staining in patients coinfected with HBV and HIV. METHODS: This is a cross-sectional study of 110 adults coinfected with HBV and HIV who underwent clinical assessment and liver biopsy. Immunohistochemistry (IHC) was performed for HBsAg and HBcAg. Viral biomarkers included quantitative HBsAg, HBV RNA, and HBcrAg. RESULTS: Participants median age was 49 years (male, 93%; Black, 51%; HBeAg+, 65%), with suppressed HBV DNA (79%) and undetectable HIV RNA (77%) on dually active antiretroviral therapy. Overall, HBV RNA and HBcrAg were quantifiable in 81% and 83%, respectively (96% and 100% in HBeAg+, respectively). HBcAg staining was detected in 60% and HBsAg in 79%. Higher HBV RNA was associated with higher HBcAg and HBsAg IHC grades (both p
- Published
- 2023